Association of interleukin-18 gene promoter polymorphisms with risk of acute myocardial infarction in northern Chinese Han population

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 5, 2009, Pages 523-529

  Pei, Fang ^a   Han, Yaling ^b   Zhang, Xiaolin ^b   Yan, Chenghui ^b   Huang, Mingfang ^b   Huang, Lan ^a   Kang, Jian ^b  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b SHENYANG NORTHERN HOSPITAL   (China)

Author keywords

Acute myocardial infarction; IL 18; Polymorphism

Indexed keywords

INTERLEUKIN 18;

ACUTE HEART INFARCTION; ADULT; ALLELE; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; INTERLEUKIN 18 GENE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT; RISK FACTOR;

CASE-CONTROL STUDIES; CHINA; FEMALE; GENE FREQUENCY; GENETIC SCREENING; HUMANS; INTERLEUKIN-18; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; QUESTIONNAIRES; RISK FACTORS;

EID: 67649172859     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.130     Document Type: Article

References (50)

1. Bonow RO, Smaha LA, Smith SC Jr, Mensah GA, Lenfant C. World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation 2002;106:1602-5.
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
3. Mauriello A, Sangiorgi G, Fratoni S, Palmieri G, Bonanno E, Anemona L, et al. Diffuse and active inflammation occurs in both vulnerable and stable plaques of the entire coronary tree: a histopathologic study of patients dying of acute myocardial infarction. J Am Coll Cardiol 2005;45:1585-93.
4. Patel S, Celermajer DS, Bao S. Atherosclerosis-underlying inflammatory mechanisms and clinical implications. Int J Biochem Cell Biol 2008;40:576-80.
5. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008;54:24-38.
6. Zernecke A, Shagdarsuren E, Weber C. Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol 2008;28:1897-908.
7. Reddy P. Interleukin-18: recent advances. Curr Opin Hematol 2004;11:405-10.
8. Anderson JL, Carlquist JF. Cytokines, interleukin-18, and the genetic determinants of vascular inflammation. Circulation 2005;112:620-3.
9. Blankenberg S, Luc G, Ducimetiere P, Arveiler D, Ferrieres J, Amouyel P, et al. Interleukin-18 and the risk of coronary heart disease in European men: the prospective epidemiological study of myocardial infarction (PRIME). Circulation 2003;108:2453-9.
10. Espinola-Klein C, Rupprecht HJ, Bickel C, Lackner K, Schnabel R, Munzel T, et al. Inflammation, atherosclerotic burden and cardiovascular prognosis. Atherosclerosis 2007;195:e126-34.
11. Caligiuri G, Kaveri S, Nicoletti A. When interleukin-18 conducts, the Preludio sounds the same no matter who plays. Arterioscler Thromb Vasc Biol 2005;25:655-7.
12. Stoll S, Jonuleit H, Schmitt E, Muller G, Yamauchi H, Kurimoto M, et al. Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. Eur J Immunol 1998;28:3231-9.
13. Bobryshev YV. Dendritic cells and their involvement in atherosclerosis. Curr Opin Lipidol 2000;11:511-7.
14. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med 2002;195:245-57.
15. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995;378: 88-91.
16. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 1997;99:2752-61.
17. Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y, et al. Expression of interleukin-18in human atherosclerotic plaques and relation to plaque instability. Circulation 2001;104:1598-603.
18. Whitman SC, Ravisankar P, Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. Circ Res 2002;90: E34-8.
19. de Nooijer R, von der Thusen JH, Verkleij CJ, Kuiper J, Jukema JW, van der Wall EE, et al. Overexpression of IL-18 decreases intimal collagen content and promotes a vulnerable plaque phenotype in apolipoprotein-E-deficient mice. Arterioscler Thromb Vasc Biol 2004;24: 2313-9.
20. Tenger C, Sundborger A, Jawien J, Zhou X. IL-18 accelerates atherosclerosis accompanied by elevation of IFN-gamma and CXCL16 expression independently of T cells. Arterioscler Thromb Vasc Biol 2005;25:791-6.
21. Mallat Z, Corbaz A, Scoazec A, Graber P, Alouani S, Esposito B, et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res 2001;89:E41-5.
22. Mallat Z, Henry P, Fressonnet R, Alouani S, Scoazec A, Beaufils P, et al. Increased plasma concentrations of interleukin-18 in acute coronary syndromes. Heart 2002; 88:467-9.
23. Rosso R, Roth A, Herz I, Miller H, Keren G, George J. Serum levels of interleukin-18 in patients with stable and unstable angina pectoris. Int J Cardiol 2005;98:45-8.
24. Hulthe J, McPheat W, Samnegard A, Tornvall P, Hamsten A, Eriksson P. Plasma interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6. Atherosclerosis 2006;188:450-4.
25. Chen MC, Chen CJ, Yang CH, Wu CJ, Fang CY, Hsieh YK, et al. Interleukin-18: a strong predictor of the extent of coronary artery disease in patients with unstable angina. Heart Vessels 2007;22:371-5.
26. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002;106:24-30.
27. Tiret L, Godefroy T, Lubos E, Nicaud V, Tregouet DA, Barbaux S, et al. Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation 2005;112:643-50.
28. Giedraitis V, He B, Huang WX, Hillert J. Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol 2001;112:146-52.
29. Dong GP, Yu ZS, Liang L, Zou CC, Fu JF, Wang CL. IL-18 gene promoter -137C/G and -607C/A polymorphisms in Chinese Han children with type 1 diabetes mellitus. Int J Immunogenet 2007;34:75-9.
30. Pawlik A, Kurzawski M, Czerny B, Gawronska-Szklarz B, Drozdzik M, Herczynska M. Interleukin-18 promoter polymorphism in patients with rheumatoid arthritis. Tissue Antigens 2006;67:415-8.
31. Takagawa T, Tamura K, Takeda N, Tomita T, Ohda Y, Fukunaga K, et al. Association between IL-18 gene promoter polymorphisms and inflammatory bowel disease in a Japanese population. Inflamm Bowel Dis 2005;11: 1038-43.
32. Zhou Y, Yamaguchi E, Hizawa N, Nishimura M. Roles of functional polymorphisms in the interleukin-18 gene promoter in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005;22:105-13.
33. Falcone C, Campo I, Emanuele E, Buzzi MP, Geroldi D, Belvito C, et al. -/A polymorphism of the RAGE gene promoter in relation to severity of coronary atherosclerosis. Clin Chim Acta 2005;354:111-6.
34. Ringqvist I, Fisher LD, Mock M, Davis KB, Wedel H, Chaitman BR, et al. Prognostic value of angiographic indices of coronary artery disease from the Coronary Artery Surgery Study (CASS). J Clin Invest 1983;71: 1854-66.
35. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53, 2003.
36. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20:1183-97.
37. Yoo JK, Kwon H, Khil LY, Zhang L, Jun HS, Yoon JW. IL-18 induces monocyte chemotactic protein-1 production in macrophages through the phosphatidylinositol 3-kinase/Akt and MEK/ERK1/2 pathways. J Immunol 2005;175:8280-6.
38. Kohka H, Yoshino T, Iwagaki H, Sakuma I, Tanimoto T, Matsuo Y, et al. Interleukin-18/interferon-gamma-inducing factor, a novel cytokine, up-regulates ICAM-1 (CD54) expression in KG-1 cells. J Leukoc Biol 1998;64:519-27.
39. Puren AJ, Fantuzzi G, Gu Y, Su MS, Dinarello CA. Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J Clin Invest 1998; 101:711-21.
40. Abraham M, Shapiro S, Lahat N, Miller A. The role of IL-18 and IL-12 in the modulation of matrix metalloproteinases and their tissue inhibitors in monocytic cells. Int Immunol 2002;14:1449-57.
41. Nold M, Goede A, Eberhardt W, Pfeilschifter J, Muhl H. IL-18 initiates release of matrix metalloproteinase-9 from peripheral blood mononuclear cells without affecting tissue inhibitor of matrix metalloproteinases-1: suppression by TNF alpha blockage and modulation by IL-10. Naunyn Schmiedebergs Arch Pharmacol 2003;367: 68-75.
42. Bis JC, Heckbert SR, Smith NL, Reiner AP, Rice K, Lumley T, et al. Variation in inflammation-related genes and risk of incident nonfatal myocardial infarction or ischemic stroke. Atherosclerosis 2008;198:166-73.
43. Liu W, Tang Q, Jiang H, Ding X, Liu Y, Zhu R, et al. Promoter polymorphism of interleukin-18 in angiographically proven coronary artery disease. Angiology 2008.
44. Hernesniemi JA, Karhunen PJ, Rontu R, Ilveskoski E, Kajander O, Goebeler S, et al. Interleukin-18 promoter polymorphism associates with the occurrence of sudden cardiac death among Caucasian males: the Helsinki Sudden Death Study. Atherosclerosis 2008;196:643-9.
45. Evans J, Collins M, Jennings C, van der Merwe L, Soderstrom I, Olsson T, et al. The association of interleukin-18 genotype and serum levels with metabolic risk factors for cardiovascular disease. Eur J Endocrinol 2007;157:633-40.
46. Kuller LH. Ethnic differences in atherosclerosis, cardiovascular disease and lipid metabolism. Curr Opin Lipidol 2004;15:109-13.
47. Hiromatsu Y, Mukai T, Kaku H, Miyake I, Ichimura M, Fukutani T, et al. IL-18 gene polymorphism confers susceptibility to the development of anti-GAD65 antibody in Graves' disease. Diabet Med 2006;23:211-5.
48. Lee YJ, Kang SW, Park JJ, Bae YD, Lee EY, Lee EB, et al. Interleukin-18 promoter polymorphisms in patients with Behcet's disease. Hum Immunol 2006;67:812-8.
49. Segat L, Milanese M, Arosio B, Vergani C, Crovella S. Lack of association between Interleukin-18 gene promoter polymorphisms and onset of Alzheimer's disease. Neurobiol Aging 2008.
50. Farhat K, Hassen E, Bouzgarrou N, Gabbouj S, Bouaouina N, Chouchane L. Functional IL-18 promoter gene polymorphisms in Tunisian nasopharyngeal carcinoma patients. Cytokine 2008;43:132-7.